Literature DB >> 3664427

Effect of natural beta-interferon on cell proliferation and steroid receptor level in human breast cancer cells.

G Sica1, V Natoli, C Stella, S Del Bianco.   

Abstract

The effect of natural beta-interferon (beta-IFN) on cell proliferation and steroid receptor level was investigated in CG-5 human breast cancer cell line. beta-interferon determines an appreciable diminution of cell growth, at concentrations ranging from 100 to 1000 IU/ml, which is enhanced when serum content of the culture medium is lowered. Low concentrations of beta-IFN (10-100 IU/ml) produce, after a 5-day treatment, an increase in estrogen receptors (ER) and progesterone receptors (PR). No variation of ER and PR levels is observed when beta-IFN is added directly to the cell homogenate before the assay. Our data suggest that beta-IFN could affect hormone sensitivity through a modification of ER and PR in neoplastic mammary cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3664427     DOI: 10.1002/1097-0142(19871115)60:10<2419::aid-cncr2820601011>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  22 in total

1.  IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis.

Authors:  Yanxia Ning; Rebecca B Riggins; Jennifer E Mulla; Haniee Chung; Alan Zwart; Robert Clarke
Journal:  Mol Cancer Ther       Date:  2010-05       Impact factor: 6.261

Review 2.  Biological response modifiers in the management of patients with breast cancer.

Authors:  D L Longo; L C Hartmann
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

Review 3.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

4.  Antiproliferative effect of interferons on human prostate carcinoma cell lines.

Authors:  G Sica; L Fabbroni; L Castagnetta; M Cacciatore; M Pavone-Macaluso
Journal:  Urol Res       Date:  1989

5.  Tamoxifen and interferon-beta for the treatment of metastatic breast cancer.

Authors:  L Repetto; P G Giannessi; E Campora; P Pronzato; A Vigani; C Naso; I Spinelli; P F Conte; R Rosso
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

6.  Phase II trial of recombinant beta (IFN-betaser) interferon in the treatment of metastatic breast cancer.

Authors:  L Barreras; C L Vogel; G Koch; S G Marcus
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

7.  Androgen receptors and hormone sensitivity of a human prostatic cancer cell line (PC-3) are modulated by natural beta-interferon.

Authors:  G Sica; G Dell'Acqua; F Iacopino; A Fattorossi; P Marchetti; T H van der Kwast; M Pavone-Macaluso
Journal:  Urol Res       Date:  1994

8.  Biochemical and immunological responses of hairy cell leukemia patients to interferon beta.

Authors:  A M Liberati; M Horisberger; M Schippa; F Di Clemente; M Fizzotti; S Filippo; M G Proietti; S Arzano; P Berruto; L Palmisano
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

9.  Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer.

Authors:  J E Macheledt; A U Buzdar; G N Hortobagyi; D K Frye; J U Gutterman; F A Holmes
Journal:  Breast Cancer Res Treat       Date:  1991-08       Impact factor: 4.872

10.  Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse.

Authors:  D F Gibson; D A Johnson; D Goldstein; S M Langan-Fahey; E C Borden; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.